(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 9 September 2005 (09.09.2005)

PCT

(10) International Publication Number WO 2005/082458 A1

(51) International Patent Classification⁷: A61P 35/00, A61K 31/711, 31/7105, 31/713, 31/37, 31/565

(21) International Application Number:

PCT/US2005/005508

- (22) International Filing Date: 22 February 2005 (22.02.2005)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/547,010

23 February 2004 (23.02.2004) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 60/547,010 (CON)

Filed on


23 February 2004 (23.02.2004)

(71) Applicants (for all designated States except US): ILEX PRODUCTS, INC. [US/US]; 4545 Horizon Hill Blvd., San Antonio, TX 78229-2263 (US). DANA-FARBER **CANCER INSTITUTE, INC.** [US/US]; 44 Binney Street, Boston, MA 02115 (US).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KUFE, Donald, W. [US/US]; 179 Grove Street, Wellesley, MA 02181 (US). KHARBANDA, Surender [US/US]; 8 Jacqueline Circle, Natick, MA 01760 (US).
- (74) Agent: MOLONEY, Steven, J.; Fulbright & Jaworski, LLP, Suite 2400, 600 Congress Avenue, Austin, TX 78701 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: MUC1 ANTAGONIST ENHANCEMENT OF DEATH RECEPTOR LIGAND-INDUCED APOPTOSIS



(57) Abstract: The present invention relates to methods of enhancing death receptor-induced apoptosis in MUC1 expressing cells comprising contacting the MUC1 expressing cells with an effective amount of a MUC1 antagonist.

WO 2005/082458 A1



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

with international search report